VSY Biotechnology GmbH, a biotechnology company with core competencies in the fields of ophthalmology and orthopedics, is counting down the hours until the launch of its brand-new and one-of-a-kind Trifocal IOL at the Satellite Symposium on Sunday, 10 October at 15:15 at the 39th congress of ESCRS.
With its new Trifocal lens, the company introduces the concept of Golden Ratio in IOL TechnologyTM with AcrivaUD Trinova Pro C Pupil AdaptiveTM for cataract and RLE (Refractive Lens Exchange) patients to provide the highest level of visual quality and spectacle independence at all distances and in every possible lighting condition.
The new lens uses patented Sinusoidal Vision Technology (SVT®), a proprietary design that optimizes to distribute effective and efficient light energy into the near and intermediate distances, while maintaining distance visual acuity due to minimized light loss in the diffraction orders provided by enhanced light distribution with patented Sinusoidal Vision Technology (SVT®).
AcrivaUD Trinova Pro C Pupil Adaptive® will be available by +1.8D intermediate and +3.6D near addition dioptric powers in the IOL plane.
The new lens will be commercially available after its launch at the ESCRS Congress.
The panel will be moderated by Dr. Ike Ahmed –the Rock Star of Ophthalmology. Dr. Hakan Kaymak will be presenting Optical Bench Results and Optical Design of Enhanced Sinusoidal Vision Technology (SVT®) and Dr. Karsten Klabe will be highlighting Clinical Results of "AcrivaUD Trinova Pro C Pupil Adaptive®” at the satellite symposium, the company announced in a news release.
Between 16:05-16:15, VSY Biotechnology will be announcing the winners of its Ophthalmology Star Awards.
VSY Biotechnology will also be exhibiting on the showroom floor throughout ESCRS at booth D29-Hall 12.